

# National Institute for Health and Care Excellence

## Obesity (update)

### Stakeholder Comments – Draft Scope

<p><b><u>NOTE:</u></b></p> <p>NICE is unable to accept comments from non-registered organisations or individuals. If you wish your comments to be considered but are not a registered stakeholder, please register via the <a href="#">NICE website</a> or contact the <a href="#">registered stakeholder organisation</a> that most closely represents your interests and pass your comments to them.</p> <p>Please fill in both the ‘stakeholder organisation’ and ‘name of commentator’ fields below in order for your comments to be considered.</p>		
<p><b>Stakeholder organisation:</b></p>		<p><u>Royal Pharmaceutical Society</u></p>
<p><b>Name of commentator:</b></p>		<p><u>Katie Perkins</u></p>
Comment No.	Section number	Comments
	<p>Indicate <b>number</b> or <b>‘general’</b> if your comment relates to the whole document</p>	<p>Please insert each new comment in a new row.</p> <p>Please do not paste other tables into this table, as your comments could get lost – type directly into this table</p>
Example	3.4.6	Our comments are as follows .....
<p><b>Proformas that are not correctly submitted as detailed in the line above may be returned to you.</b></p>		
1	General	<p>The Royal Pharmaceutical Society welcomes evidence-based clinical guidance on the prevention, identification, assessment and management of overweight and obesity in children, young people and adults, and agrees with the areas that NICE propose to update and the new areas it will cover.</p> <p>Pharmacists have a significant role in raising awareness of the health risks associated with being overweight, providing advice on healthy lifestyles and also supplying medicines and nutritional products to help patients manage their weight.</p> <p>The accessible and inviting environment of pharmacies in the community, allow people to seek advice and have conversations about weight management at a time that is convenient for them, without having to make an appointment.</p>

PLEASE NOTE: The Institute reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of the Institute, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.

2	4.3	We have noted that NICE does not plan to update CG43 section 1.2.5 Pharmacological Interventions, and that the changes made to the guidance regarding sibutramine in 2010 (following the suspension of its marketing authorisation) are currently communicated in the form of notes within the original guidance. Would this be a good opportunity to reconcile this section of the guidance?
---	-----	---

Please add extra rows as needed.

**Please email this form to: [Obesity@nice.org.uk](mailto:Obesity@nice.org.uk)**

**Closing date: 5pm on 11 Dec 2013**

PLEASE NOTE: The Institute reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of the Institute, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.